Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I suspect with him at a new venu we may not see him on this board again. I'm curious if he's dropped the Col. Jessup reference too as every time I've watched A Few Goood Men Jessup was a criminal.
Me too, he is a talent, and the Hip's music has helped some close to me endure SOC in their battle with cancer. If the GBM comes back there is upcoming trial at UCLA for recurrent GBM which is also a combo trial with CI. Not sure if the protocol Includes a second surgery, Senti and/or Flip or others may be more familiar with the protocol.
joeycav11, Sound thoughts and ramblings. Will be interesting if recent volume increase is sustainable. On another subject/rambling, and one were devoid of news on in the states. How is Gord Downie doing in his battle with GBM?
Ball buster!
Also intersting to note Cofer joined board as independent director in January 2016. And apparently after digging into things decided to participate in a recent financing April 2017.
Posted below about BMY's biologic expansion in Ireland two years ago. The buildout of the facility is completed. A high level of activity in the next 18 to 24 months as they will be working towards validation and agency approval EMA, FDA, Irish Medicines Board, and other agencies from countries product is expected to be shipped. The facility is planned to be online in 2019.
Know-Fear Sunday, 06/21/15 11:58:35 PM
Re: None
Post # of 124745
What level of investment required to establish biologics production on two continents? For BMY it's nearly 2 billion dollars and their second facility won't be operational until 2019
Bristol-Myers Squibb to Build Biologics Plant in Ireland
Pharmaceutical Company Expects to Invest About $900 Million in New Facility
By
Michael Calia
Nov. 14, 2014 6:30 a.m. ET
0 COMMENTS
Bristol-Myers Squibb Co. on Friday said it plans to build a biologics plant in Cruiserath, Ireland, as the pharmaceutical company expands its global manufacturing presence.
Bristol-Myers said it expects the cost of the new plant to be comparable to the roughly $900 million it paid to build a biologics facility in Devens, Mass. The company said it expects to finalize the cost of the new plant during the second half of 2015.
Bristol-Myers said it expects about 350 to 400 scientists, engineers and other staffers to work at the Ireland site once construction is completed. The company projects the facility will be operational in 2019.
The move comes as biologic medicines are being used increasingly to treat major diseases, the company said, adding that the drugs make up more than half of its research-and-development pipeline.
Ireland has become a hot spot for the pharmaceutical industry, as U.S. companies have sought to expand in the country through so-called inversion deals that lower tax bills.
Write to Michael Calia at michael.calia@wsj.com
The Penguin type cold caps were approved by FDA in December 2015. The DigiCaps are a mechanical cooling cap system added to the approval list. Mechanical system will be more comfortable as you can bring down temp slowly and maintain consistent temperature. As you point out the first cap going on with the Penguin style caps is the toughest one for the participant.
NWDR,
It sounds to me the folks at Penguin got the word and adjusted the protocol. Both times I participated we had 30 minute cycle times (after the fist two caps). With the 20 minute cycle don't think you need to check temp coming off. The other area where we hedged was on cap temp going on. My coolers are the slightly larger 70 qt size and we packed 50lbs (25% more) of dry ice in each with the caps. Hence the cap temperatures going on were routinely in the -30F to -40F/C range. And we were more aggressive during the Adriamycin cycles than the other cycles.This woman's thick full head of hair provided more insulation as this maneuver was a bit of a risk. Again I think your better served with the shorter cycle time as colder caps are riskier. Albeit the shorter cycle times are going to keep you busy.
NWDR, I've assisted twice in the application of Penguin cold caps and they worked both times. Second time was an intense chemo regimen which included adriamycin. Since the caps and their heavy dense liquid act as a heat sink one of tricks I would do is measure the temperature of the just removed caps. Kind of a barometer of relative scalp temperature if you will. If the ones coming off were relatively warm 20+F I would shorten the length of the next cap application by a few minutes to bring down the relative scalp temperature.
My hope and thoughts are with you and your wife.
This story unfolding might interest some as we wait for news here.
http://www.afr.com/news/world/plunge-in-innate-immunotherapeutics-shares-costs-us-congressman-22m-20170627-gwzzc2
What's the current over/under on needle size and number of injections?
May need to welcome a new person/entity to the party. I see some lawyers are also able to find/create work for themselves.
Milner, that was a well thought out and coherent analogy. Hence it took a decade or so to begin to have the infrastructure in place (bandwidth) to support the coming flood of smart devices that enabled social media to take off......Or was it possible in 1994 with a 14400 baud modem tying up the single phone line (the good old days)
Don't think you'll get any arguments from anyone here, no matter their relative positions, on OS being the gold standard.
Don't think there will be any positive PR's today or this week. Today is the proverbial "big news day" with the circus in DC and our friends in the U.K. have their Snap election (I thought they snapped last year and they likely think the same about us). On the other hand timing would be opportune for a negative PR (not stating that is going to happen) with all the noise.
Saw the slide on Monday and simply based on names assumed some of the "investigators" are German. Recognized a fair amount of U.S. investigators and assumed the balance to be U.K.
Conflicted is the word......
Not as biting when one needs to manufacture a narrative.
Classy move by LP. Also encouraging for AF to pick himself up and get off the street. Albeit too often these stories end up in relapse or recidivism........lets hope not.
Agree Bosch did good job on presenting trial/clinical/medical aspects of both L and D. He's not the guy nor is the ASCO Industry Expert theater the forum to present business matters than can effect SP. He did set the table and I hope NWBO plans to follow up with the latter.....on the platter.
Yes, I think it is NICE they are working towards publishing the data.
Both end points are independently powered.
Need meat l'm cutting down/out the carbs.....
Good a live webcast. Should broaden the audience.
I think the last presentation was two years ago. There is a link available on the ihub NWBO intro.
AF also "victimized" (used very loosely) by proxy battle, but will come out smelling like a rose (also used very loosely) by being out of The Street before they get their delisting notice. (Better than being on the street after.....)
As for Bosch's presentation on Tuesday there will be plenty of "covfefe" from more than AF if Marnix doesn't provide some meat. At this point not many as giddy as Sparky as most have experienced the ASCO rodeo before which tempers their current expectations.
IMO this is the fist position posted recently that most likely relates to cultivating and integrating other new business opportunities at Cognate. Whereas as all the other recent postings have been related to scaling up commercialization/production capability. Noticed the link I provided earlier this year to the architecture/building firm involved in the Cognate expansion is no longer shows the Cognate expansion. Since the link showed projects "under construction" I'll assume the "construction" portion is complete. Also as a side note I saved a copy of the Cognate expansion image when I came upon it in November 2015. Admittedly (also as a nod to the positions of ex and others) the 16 cleanrooms suits could be used for multiple customers. However, there is also a significant amount of unused space in the expansion. I don't think Cognate is going to pay to light/heat/cool this space without a plan to generate revenue and it's likely one of the tasks for the "project manager".
Covfefe!
I would agree too in some form/fashion the two could merge.
Believe location and MO have been consistent in the recent past.
Cayman Islands.........how's the diving?
In regards to ASCO (agree) it appears the focus of the presentation will be on Direct. However in regards to L would appreciated if Bosch would connect the dots on the hold especially if there was/is manufacturing related content being addressed.
Exactly. Welcome back.
If Woody's gone soft BP is fraught with remedies to rectify....
Is this the first listing for a third shift position?
A special counsel?
Stick a fork in the the quarterly drama "Did Woody Sell?" indeed.
Ricardo......dudes with pseudonyms. Would be interesting to find out any MB "pseudonyms" of Ricardo's.
No doubt FedEx will handle the lions share. I think the message they're attempting to covey is they can utilize both of international carriers networks to ensure timely deliver. As there will be instances where UPS either serves a destination FedEx doesn't or can get there faster (going through Louisville) depending on the day of the week. More likely or frequently the latter
Chalk this up to not that it matters, but Louisville is UPS's worldwide shipping hub. They can ship worldwide via UPS from Memphis, but it's going through Louisville first.